Biotech
-
GSK’s ViiV to expand supply of HIV drug in Africa
The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and…
Read More » -
Editas trades Vertex fees for upfront cash in DRI deal
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an…
Read More » -
Medicare tweaks rules for second round of drug price talks
The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.
Read More » -
With $115M more, Triveni accelerates immune drug work
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start…
Read More » -
Key factors shaping the future of clinical services organizations in the APAC market
Clinical services organizations can help pharma with global drug development and clinical trial challenges.
Read More » -
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen…
Read More » -
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Despite working in a restrictive funding climate, the prolific startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing…
Read More » -
Biogen, UCB get the lupus data they’ve waited two decades for
The companies now plan on starting this year another large study of their drug, dapirolizumab pegol, in the hopes that they can…
Read More » -
FTC sues major pharmacy benefit managers over insulin prices
The agency brought action against Caremark, Express Scripts and Optum Rx on Friday, and warned that all drug manufacturers “should be…
Read More » -
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing…
Read More »